Shamburg News · 8-K filed Oct 30, 2026, 5:10 PM EDT
Annovis Bio Receives NYSE Notice of Noncompliance With Market Cap and Equity Continued Listing Standard
ANVS · Annovis Bio, Inc.
- Delisting
- Other event
- Reg FD disclosure
- Materiality: high
On October 29, 2026, Annovis Bio, Inc. received a notice from the New York Stock Exchange stating it was no longer in compliance with Section 802.01B because its 30 trading-day average market capitalization was below $50 million while its stockholders' equity was below $50 million. The notice cited an approximate $48.4 million average market capitalization as of October 28, 2026 and an approximately $(4.3) million stockholders' deficit as of June 30, 2026. The Company stated it will submit a compliance plan within 45 days and must regain conformity within 9 months, and that its common stock will continue to trade on the NYSE under “ANVS” with a “.BC” designation during the cure period.
Source: SEC EDGAR, Form 8-K, Items 3.01, 7.01, 9.01, accession 0001104659-26-120732.
Written from the filing by Shamburg Markets. Figures are as reported by the company.